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Purpose: Pulmonary toxicities, including infectious pneumonia (IP) and idiopathic pneumonia syndrome (IPS), are serious side 
effects of total body irradiation (TBI) used for myeloablative conditioning. This study aimed to evaluate clinical factors associated 
with IP and IPS following TBI. 
Materials and Methods: Fifty-eight patients with hematologic malignancies who underwent TBI before allogeneic 
hematopoietic stem cell transplantation between 2005 and 2014 were reviewed. Most patients (91%) received 12 Gy in 1.5 Gy 
fractions twice a day. Pulmonary toxicities were diagnosed based on either radiographic evidence or reduced pulmonary function, 
and were subdivided into IP and IPS based on the presence or absence of concurrent infection. 
Results: Pulmonary toxicities developed in 36 patients (62%); 16 (28%) had IP and 20 (34%) had IPS. IP was significantly 
associated with increased treatment-related mortality (p = 0.028) and decreased survival (p = 0.039). Multivariate analysis revealed 
that the risk of developing IPS was significantly higher in patients who received stem cells from a matched unrelated donor than 
from a matched sibling donor (p = 0.021; hazard ratio [HR] = 12.67; 95% confidence interval [CI], 1.46–110.30). Combining other 
conditioning agents with cyclophosphamide produced a higher tendency to develop IP (p = 0.064; HR = 6.19; 95% CI, 0.90–42.56).
Conclusion: IP and IPS involve different risk factors and distinct pathogeneses that should be considered when planning 
treatments before and after TBI. 
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Introduction
Total body irradiation (TBI) is a radiotherapy technique 
frequently used as a component of hematopoietic stem 
cell transplantation (HSCT). TBI used in conjunction with 
chemotherapeutic agents has proven to be useful for 
eradicating residual malignant or genetically abnormal cells. 
It is also used for immunosuppression prior to HSCT, and its 
accessibility to so-called sanctuary sites is a major advantage 
[1,2]. However, various acute and late side effects that include 
gastrointestinal symptoms, cataract, hepatic veno-occlusive 
disease, and renal complications can develop after TBI-based 
HSCT, and can sometimes be life-threatening [3,4]. Among 
the serious side effects related to TBI-based HSCT, pulmonary 
toxicity was the single major reason for transplantation-
associated deaths, with an incidence rate of up to 62% and a 
mortality rate of up to 65% in early studies [5,6]
Pulmonary toxicities following HSCT can result from 
infectious and/or noninfectious etiologies. Infectious 
etiologies typically include bacterial , viral, or fungal 
pneumonia; noninfectious etiologies are best characterized 
by the presumed site of primary tissue injury. In 1993, the 
term idiopathic pneumonia syndrome (IPS) was proposed 
to describe widespread alveolar injury in the absence of 
active lower respiratory tract infection after bone marrow 
transplantation [7]. The two types of pulmonary toxicities, 
infectious pneumonia (IP) and IPS, are considered distinct 
disease entities because they have different etiologies, 
treatments, and prognoses. Various clinical parameters have 
been studied to identify factors associated with pulmonary 
toxicity after TBI-based HSCT. However, the factors that 
influence the development of IP and IPS after TBI-based 
stem cell transplantation remain controversial [8-10]. Given 
the distinct pathogeneses of the two types of pneumonia, 
we hypothesized that IP and IPS have their own unique risk 
factors. A better understanding of such risk factors related 
to IP and IPS is important because even though several 
investigators have attempted to reduce pulmonary toxicities by 
modifying radiation-related factors such as dose-rate or total 
dose, these fatal toxicities have not been completely prevented 
and still result in high mortality rates [10,11]. Our aim was to 
identify the clinicpathological factors associated with IP and 
IPS that develop after fractionated TBI administered as a part 
of a myeloablative conditioning regimen before HSCT. 
Materials and Methods
1. Patient population
We retrospectively reviewed 69 patients with hematologic 
malignancies who received TBI as part of a conditioning 
regimen before allogeneic stem cell transplantation between 
January 2005 and December 2014 at Yonsei Cancer Center. 
According to our institution’s treatment protocol, TBI-based 
myeloablative conditioning was performed only for patients 
with high-risk, very high-risk, or refractory hematologic 
malignancies. Patients who received autologous stem cell 
transplantation (n = 6) or nonmyeloablative TBI (n = 5) were 
excluded; those who underwent stem cell transplantation 
without TBI were not analyzed. Fifty-eight patients were 
ultimately eligible for this analysis.
2. Stem cell transplantation procedure
All patients underwent a standard pre-HSCT evaluation, 
including a pulmonary function test, complete blood count, 
and chemistry profile. If cardiopulmonary, hepatic, and 
renal functions remained adequate, TBI-based conditioning 
regimens were initiated before the HSCT. Chemotherapy 
conditioning prior to TBI was generally performed using 
high-dose cyclophosphamide (51 of 58 cases). Variations in 
the regimen were influenced by underlying diseases, risk of 
complications, and patient preference. TBI was performed for 
4 days from day −8 to day −5, after which patients received 
high-dose cyclophosphamide (60 mg/kg in 2 doses on days 
−3 and –2). Intrathecal methotrexate was administered on 
day –3 for central nervous system prophylaxis. From the day 
of initiation of TBI, micafungin, acyclovir, and trimethoprim-
sulfamethoxazole were used for antifungal prophylaxis, 
antiviral prophylaxis, and prophylaxis against Pneumocystis 
jirovecii, respectively. 
3. TBI technique
Generally, a simulation was performed in the treatment 
position 1 week before the initiation of TBI. Thickness 
measurements were obtained for the patients at the 
prescription point and at other points of interest for dose 
calculations and determination of homogeneity, such as 
measurements of the head, neck, shoulder, lung, mediastinum, 
xiphoid, pelvis, thigh, knee, calf, and ankle. An individualized 
lead compensator was made to homogenize the whole-
body dose to within ±5% in all patients. Calculations were 
performed by a qualified medical physicist to achieve the 
prescribed dose, dose homogeneity, and any other relevant 
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dose points. Patients were placed in the supine position, with 
whole-body vacuum immobilization against the far wall of the 
linear accelerator room to achieve maximum source-to-surface 
distance and field size in order to encompass the entire body. 
If the patients were too tall to fit into the field-range, a bent-
knee posture was adopted; otherwise, the patients lay with their 
legs straightened. Treatment was administered using a linear 
accelerator with 10 MV photons, bilateral parallel opposing 
fields, and an extended source-to-axis distance (SAD = 390 
cm). Thermoluminescence dosimetry was applied to the head, 
neck, chest (surface and lateral), and pelvis, as well as to the 
medial sides of the thigh, knee, and malleolus. Total TBI doses 
ranged from 8 to 12 Gy; most of the patients (91%) received 
12 Gy. All patients received fractionated TBI in mostly 1.5 Gy 
fractions (94.8%) twice a day. Both the lungs were intended 
to receive the prescribed radiation dose. We did not perform 
lung dose reduction. Both arms of the patient were laid down 
along the sides of the body such that the shadow of the arms 
would partially cover the lungs. To compensate the low density 
of the lung, lead compensators were designed considering the 
thickness of an arm. The dose rate was between 7 and 19 cGy/
min. In November 2011, the specific TBI guideline used by our 
treatment team was partially modified, and the dose rate was 
increased from 5–10 to 12–20 cGy/min. The dose rate was 
then subtly adjusted according to each patient’s condition; co-
morbidities (such as a prior history of pneumonia) were always 
considered. 
4. Follow-up, assessment, and definition of pulmonary 
toxicity
Patients were hospitalized for at least for 1 month post-
HSCT until their acute toxicity was managed sufficiently. After 
discharge, regular examinations including chest radiography, 
physical examination, bone marrow aspiration, and a complete 
blood count were performed at regular visits that occurred 
with intervals of 1–2 months during the first year, 3 months 
during the second year, and 6 months thereafter. Baseline 
pulmonary function tests were obtained within 1 month 
before TBI. The diffusion capacity of carbon dioxide was 
determined using a carbon monoxide single-breath technique 
with correction for hemoglobin concentration. Patients with 
clinical pulmonary symptoms, such as dyspnea/cough or any 
indication of respiratory symptoms, were defined as having 
pulmonary toxicity only if they showed radiographic evidence 
or reduced pulmonary function; this was to reduce the false-
positive rate. Pulmonary toxicity was further subdivided based 
on the presence or absence of concurrent infection. IPS was 
defined as pulmonary toxicity with no signs of infection, 
whereas IP was defined as pulmonary toxicity with signs 
of infection in the blood, bronchoalveolar lavage, or other 
specimens. Cultures, serological tests, and/or polymerase chain 
reaction were used to identify IP-causing pathogens in the 
specimens.
5. Survival outcomes
The actuarial overall survival (OS) was calculated as the 
duration between the end of TBI and either death or the last 
follow-up date. Treatment-related mortality (TRM) was defined 
as any death from any cause other than relapse or refractory 
disease, as described in previous studies [12,13]. Acute graft-
versus-host disease (GVHD) was graded using the Glucksberg 
grading system, where each of the three organs (skin, 
gastrointestinal tract, and liver) is staged from 0 to 4; staging 
includes objective assessment of organ function and subjective 
assessment of performance status. According to the grading 
system, Grades 1–2 included cases with mild-to-moderate skin 
changes, no or mild gastrointestinal involvement, and no or 
mild decreases in clinical performance; Grades 3–4 included 
more serious diseases [14]. 
6. Statistical analysis
The relationship between pulmonary toxicity and clinical and 
therapeutic factors such as age, sex, disease types, dose rate, 
total dose, acute GVHD, use of methotrexate for prophylaxis 
against acute GVHD, transfusion cell type, number of complete 
remissions, donor type, conditioning chemotherapy regimens, 
and pre-transplantation pulmonary function were further 
investigated. The associations of IP and IPS with other clinical 
variables on univariate and multivariate analyses were 
examined using binary logistic regression. Because it was 
unclear whether the clinical characteristics of the patients 
who died early without developing pulmonary toxicity affected 
the occurrence of the event, patients who died within 6 
months after TBI (n = 9) were excluded from the univariate 
and multivariate logistic regression analyses. This exclusion 
was regarding the typical onset of pulmonary toxicities of 
1–6 months, and to reduce the potential underestimation 
problem. Multivariate analysis of IP and IPS was conducted by 
including factors with a p-value <0.10 on univariate analysis; 
a backward variable selection method was used with an alpha 
level of removal of 0.1. A two-sided p-value of <0.05 was 
considered significant. OS was estimated using the Kaplan-
Meier method, and a log-rank test was used to assess the 
difference between patients with and without pulmonary 
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toxicities. TRM and cumulative incidences of IPS and IP were 
estimated with competing risks analyses; TRM & relapse and 
IPS & IP were considered as competing risks, respectively. 
The comparisons between subgroups were performed using 
the Gray’s test [1,2]. We used the R package ‘cmprsk’ for the 
analyses (v2.2-7, https://CRAN.R-project.org/package=cmprsk) 
with R software (https://www.R-project.org/). All other 
analyses were performed using SPSS ver. 20.0 (IBM, Armonk, 
NY, USA).
Results
1. Patients and treatment characteristics
Fifty-eight patients were eligible for the study. The median 
follow-up was 15 months (range, 13 days to 132 months). 
Patient characteristics and treatment details are listed in 
Table 1. Most patients were treated for acute lymphoblastic 
leukemia (74.1%) or myelogenous leukemia (13.8%). Five 
patients had lymphoma (8.6%), 1 had neuroblastoma 
(1.7%), and 1 had Ewing sarcoma (1.7%). The conditioning 
regimens used with TBI were cyclophosphamide alone and 
cyclophosphamide plus other agents in 42 and 9 patients, 
respectively; other agents included etoposide (n = 4), etoposide 
plus imatinib (n = 1), fludarabine (n=2), cytarabine (n=1), and 
antithymocyte globulin (n=1). Pre-transplantation pulmonary 
comorbidities developed in 5 patients before the initiation of 
the preparative regimen. These included atypical pneumonia 
(n = 1), pulmonary tuberculosis (n = 1), EBV pneumonitis 
(n = 1), fungal pneumonia (n = 1), and pneumonia of 
unknown etiology (n = 1), all of which were well controlled 
or completely treated at the time of transplantation. Stem 
cells were derived from a matched sibling (20.7%), a matched 
unrelated (70.7%), or a mismatched related (8.6%) donor. Stem 
Table 1. Patients' characteristics (n = 58)
Characteristic Value
Age (yr)
 <20
 ≥20
Sex
 Female
 Male
Disease
 ALL
 AML
 Other
Total dose
 8 Gy (2.0 Gy × 4 fx, once daily)
 9 Gy (1.5 Gy × 6 fx, twice daily)
 9.6 Gy (1.2 Gy × 8 fx, twice daily)
 12 Gy (2.0 Gy × 6 fx, twice daily)
 12 Gy (1.5 Gy × 8 fx, twice daily)
Dose rate (cGy/min)
 5–9.99
 10–14.99
 ≥15
Donor type
 Matched sibling
 Matched unrelated
 Mismatched related
Cell type
 Bone marrow
 Peripheral blood
 Cord blood
Conditioning regimen group
 Cy
 Cy+other
 Other
Acute GVHD prophylaxis
 No MTX
 Yes MTX
(If leukemia) CR number
 Refractory
 CR1
 ≥CR2
preFEV1
preFVC
preDLCO
Smoking history
 No
 Yes
Pre-transplant pulmonary comorbidity
 No
 Yes
38 (65.5)
20 (34.5)
22 (37.9)
36 (62.1)
43 (74.1)
8 (13.8)
7 (12.1)
1 (1.7)
2 (3.4)
1 (1.7)
1 (1.7)
53 (91.4)
20 (34.5)
20 (34.5)
18 (31.0)
12 (20.7)
41 (70.7)
5 (8.6)
22 (37.9)
33 (56.9)
3 (5.2)
42 (72.4)
9 (15.5)
7 (12.1)
14 (24.1)
44 (75.9)
3 (5.9)
31 (60.8)
17 (33.3)
87.9 (50.0–127.0)
86.1 (56.1–131.0)
66.0 (51.0–80.0)
53 (91.4)
5 (8.6)
53 (91.4)
5 (8.6)
Values are presented as number (%) or median (range).
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; 
Cy, cyclophosphamide; GVHD, graft-versus-host disease; MTX, 
methotrexate; CR, complete response; FEV1, forced expiratory 
volume in 1 second; FVC, forced vital capacity; DLCO, diffusion 
capacity of carbon monoxide.
Table 2. Causes of death (n = 58)
Variable No. (%)
Total as of July 2016
Relapse or refractory disease related
Treatment related
 Infectious pneumonia
 Idiopathic pneumonia syndrome
 Acute graft-versus-host disease
 Acute renal failure
 Hepatic veno-occlusive disease
 Secondary malignancy
 Sedation
 Other infection
37 (63.8) 
16 (27.6) 
21 (36.2) 
7 (12.1) 
6 (10.3) 
3 (5.2) 
1 (1.7)
1 (1.7)
1 (1.7)
1 (1.7)
1 (1.7)
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cells included mobilized peripheral blood stem cells in 56.9%, 
bone marrow in 37.9%, and cord blood in 5.2% of patients. 
Post-transplant graft-versus-host prophylaxis included the use 
of methotrexate in 75.9% of patients. 
2. Treatment outcomes associated with pulmonary toxicities
In all 58 patients, the 1-, 2-, and 3-year OS rates were 53.4%, 
42.4%, and 35.2%, respectively (Fig. 1A). The 1-, 2-, and 3-year 
TRM rates were 31.0%, 33.0%, and 37.7%, respectively (Fig. 1B). 
The causes of death, including both disease-related death and 
TRM, are listed in Table 2. Thirty-seven of the 58 patients had 
died by the time of data analysis, 16 and 21 of disease-related 
and treatment-related causes, respectively. IP and IPS were 
the two leading causes of TRM, each accounting for 33.3% 
and 28.6% of all treatment-related deaths, respectively. IP was 
significantly associated with a decrease in the OS rate and an 
increase in the TRM rate. The 2-year OS rates in patients with 
and without IP were 25.0% and 49.3%, respectively (p = 0.039) 
(Fig. 2A). The 2-year TRM rates in patients with and without 
IP were 56.3% and 24.1%, respectively (p = 0.028) (Fig. 2B). In 
contrast, IPS had no significant association with either the OS 
rate (p = 0.264) or the TRM rate (p = 0.669) (Fig. 2C, 2D).
3. Clinical factors associated with developing pulmonary 
toxicities
Overall, pulmonary toxicities developed in 36 patients (62%); 
16 (28%) had a concurrent infection while 20 (34%) exhibited 
no detectable pathogens. The leading etiology of IP was 
bacterial (75%), followed by fungal (38%), and viral (12.5%). 
The median time from HSCT to the onset of pulmonary toxicity 
was 6 (range, 1 to 31) months in patients with IP and 7 (range, 
0 to 26) months in patients with IPS. In all 58 patients, the 1-, 
2-, and 3-year cumulative incidence rates of IPS were 31.0%, 
33.0%, and 37.7%, respectively, and the 1-, 2-, and 3-year 
cumulative incidence rates of IP were 25.9%, 29.7%, and 
31.8%, respectively (Fig. 3).
Clinical factors associated with pulmonary toxicities 
according to univariate and multivariate analyses are listed 
in Tables 3 and 4. Among the clinical variables analyzed in 
the univariate analysis, four factors (donor type, cell type, 
conditioning regimen, acute GVHD prophylaxis) with a p-value 
<0.10 on univariate analysis are included in the multivariate 
analysis. On univariate analysis, IP was significantly related to 
the conditioning regimen (cyclophosphamide plus other vs. 
cyclophosphamide alone; p = 0.028; hazard ratio [HR] = 7.20; 
95% confidence interval [CI], 1.24–41.94); however, IP just 
missed the threshold for statistical significance on multivariate 
analysis (cyclophosphamide plus other vs. cyclophosphamide 
alone; p = 0.064; HR = 6.19; 95% CI, 0.90–42.56). Separately, 
IPS showed a significant association with donor type on 
univariate analysis (matched unrelated vs. matched sibling; 
p = 0.021; HR = 12.67; 95% CI, 1.46–110.30) and cell type 
(peripheral blood vs. bone marrow; p=0.031; HR = 4.09; 95% 
CI, 1.14–14.66). Of these, only the donor type was significantly 
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associated with IPS on multivariate analysis (matched 
unrelated vs. matched sibling; p = 0.021; HR = 12.67; 95% CI, 
1.46–110.30). 
Discussion and Conclusion
 Among the most common causes of treatment-related 
toxicities are pulmonary complications, which occur in 
25%–80% of patients and account for approximately 50% 
of transplantation-related deaths [10,13,15,16]. Despite 
O
ve
ra
ll 
su
rv
iv
al
 ra
te
 (%
)
A
0
25
50
75
100
12 24 36 48 60
16With IP
With IP
With IP
6 3 1 0 010 3 2 0 0
42Without IP
Without IP
Without IP
With IP
Without IP25 18 11 831 23 17 9 8 8
Months
Number at risk
Tr
ea
tm
en
t-r
el
at
ed
 m
or
ta
lit
y 
ra
te
 (%
)
B
0
25
50
75
100
12 24 36 48 60
16 5 2 0 0 010 3 0 0 0
42 21 17 11 8 826 21 16 9 8
Months
Number at risk
p=0.039 p=0.028
O
ve
ra
ll 
su
rv
iv
al
 ra
te
 (%
)
C
0
25
50
75
100
12 24 36 48 60
20With IPS 11 7 4 2 215 11 6 2 2
38Without IPS
With IPS
Without IPS Without IPS
With IPS
With IPS
Without IPS15 12 7 621 13 10 7 6 6
Months
Number at risk
Tr
ea
tm
en
t-r
el
at
ed
 m
or
ta
lit
y 
ra
te
 (%
)
D
0
25
50
75
100
12 24 36 48 60
20 14 8 4 2 218 12 7 2 2
38 17 13 8 6 623 14 12 8 6
Months
Number at risk
p=0.264 p=0.669
Fig. 2. (A) Actuarial survival curves in patients with and without IP. (B) Actuarial incidence of treatment-related mortality in patients 
with and without IP. (C) Actuarial survival curves in patients with and without IPS. (D) Actuarial incidence of treatment-related mortality 
in patients with and without IPS. IP, infectious pneumonia; IPS, idiopathic pneumonia syndrome.
Pulmonary toxicity in TBI 
263www.e-roj.orghttps://doi.org/10.3857/roj.2017.00290
the distinct characteristics of IP and IPS, most studies that 
attempted to identify factors associated with pulmonary 
toxicity have focused on non-specified types of pulmonary 
toxicity [9,16,17] or only on IPS [18,19], Moreover, previous 
studies evaluating pulmonary toxicity after transplantation 
did not necessarily distinguish between allogeneic and 
autologous stem cell transplantation [16,19], which makes 
their findings difficult to compare. The present study has 
several unique aspects compared with previous studies on 
pulmonary toxicities after TBI. First, we restricted the inclusion 
criteria to patients who underwent myeloablative allogeneic 
HSCT. Second, we applied a single standardized treatment with 
a uniform total dose, fraction dose, treatment position, and 
beam delivery system. This homogeneity in patient group and 
treatment is critical for accurate assessment of the treatment-
related toxicity because toxicity depends on the intensity 
and nature of the treatment. Finally, we separately evaluated 
clinical factors that influence IP and IPS, with the hypothesis 
that these two major pulmonary complications after TBI-based 
HSCT have their own unique risk factors.
Donor type and cell type were significantly associated with 
the development of IPS according to univariate analysis; of 
these, only the donor type was significant on multivariate 
regression analysis after adjustment. This indicates that 
patients who received allografts from a matched unrelated 
donor had a higher risk of developing IPS than those who 
received cells from a matched sibling donor, a finding that 
is consistent with previous reports. Chen et al. [17] found 
that the incidence of pneumonia was higher in patients with 
matched unrelated donors than in those with matched related 
donors, and Zhang et al. [20] found that the risks of GVHD 
and TRM increase with HLA-mismatch. Donor HLA-mismatch 
affects the development of post-transplantation pulmonary 
toxicity; however, only 5 patients received stem cells from 
an unmatched donor in the present study, 3 of who died 
within 2 months of TBI. Therefore, the association between an 
unmatched donor and IPS could not be evaluated because of 
the small subset of patients and the short survival duration. 
On univariate analysis, there was a significant increase in 
the development of IP when other agents were added to the 
cyclophosphamide/TBI-based conditioning regimen; and a 
similar trend was observed on multivariate analysis, although 
without statistical significance. A myeloablative regimen 
destroys hematopoietic cells in the bone marrow and causes 
profound neutropenia and immunodeficiency; therefore, 
opportunistic infections are major complications after 
myeloablative HSCT [21]. Several studies have revealed that 
the increased intensity of a conditioning regimen is associated 
with post-transplantation infections [22-24]. A previous study 
suggested that the number of prior chemotherapy regimens 
is an important risk factor for severe pulmonary toxicity [9]. 
We suggest that the use of additional regimens with the 
cyclophosphamide/TBI-based myeloablative conditioning 
regimen may increase the risk of post-transplantation IP. 
The relationship between radiation-related factors and the 
development of pulmonary toxicity has been strongly debated. 
Because various radiation therapy techniques are employed, 
it is difficult to draw definitive conclusions from the available 
studies. Fractionated TBI for myeloablative HSCT, typically 
with a total dose of 12–15 Gy delivered in 8–12 fractions, 
has been more commonly accepted in contemporary practice 
than single-fraction TBI [25]. All patients in the present study 
received fractionated TBI, and more than 90% received a 
total dose of 12 Gy in 1.5 Gy fractions twice a day. One of 
the remaining TBI-related issues is whether the dose rate in 
modern fractionated TBI affects pulmonary toxicity. Although 
some studies have found that the dose rate is important [10,26], 
others argue to the contrary [27,28]. In 2011, our institution 
decided to increase the dose rate from 30% to 50% while 
ensuring that it did not exceed 20 cGy/min. The new dose rate 
was adopted after considering the efficacy of the treatment, 
patient convenience, practice guidelines at the time [25], and 
previously reported data that suggested that the dose rate did 
C
um
ul
at
iv
e 
in
ci
de
nc
e 
ra
te
 (%
)
0
25
50
75
100
12 24 36 48 60
58 19 13 7 6 632 16 11 7 6
Months
Number at risk
Idiopathic pneumonia syndrome
Infectious pneumonia
Fig. 3. The cumulative incidence of idiopathic pneumonia 
syndrome and infectious pneumonia in 58 patients.
 Hwa Kyung Byun, et al
264 www.e-roj.org https://doi.org/10.3857/roj.2017.00290
not have much impact on pulmonary toxicity [27,28]. Other 
radiation-related factors such as total dose, dose per fraction, 
and radiation therapy techniques have remained the same, 
which makes comparing the effect of the dose rate between 
patients of different eras more amenable. In the present study, 
our data demonstrated that the dose rate did not significantly 
affect pulmonary toxicity (Table 3), which is consistent with 
observations is a previous study [27]. Although our sample size 
was not large enough to draw a definitive conclusion regarding 
this issue, risk stratification based on radiation-related and 
other clinical factors, such as conditioning intensity and 
donor type, are necessary to identify the subset of patients 
who are likely to develop pulmonary toxicity after stem cell 
transplantation. The importance of considering multiple clinical 
Table 3. Univariate analysis of factors associated with infectious pneumonia and idiopathic pneumonia syndrome
Variable
Infectious pneumonia Idiopathic pneumonia syndrome
OR 95% CI p-value* OR 95% CI p-value*
Age (≥20 vs. <20 yr)
Sex (male vs. female)
Disease 
 ALL
 AML
 Other
Total dose (12 vs. 8–9.6 Gy
Dose rate (cGy/min)
 5–9.99
 10–14.99
 ≥15
Donor type
 Matched sibling
 Matched unrelated
 Mismatched related
Cell type
 Bone marrow
 Peripheral blood
 Cord blood
Conditioning regimen
 Cy
 Cy + other
 Other
Acute GVHD prophylaxis (yes MTV vs. no MTX)
Smoking history (yes vs. no)
Pre-transplant pulmonary comorbidity (yes vs. no)
Acute GVHD
 No
 Grade 1–2
 Grade 3–4
CR group
 CR1
 ≥CR2
 Refractory
PreFEV1 (per % increase)
PreFVC (per % increase)
PreDLCO (per % increase)
1.05 
0.57 
1 (reference)
0.82 
NA
0.22 
1 (reference)
1.63 
0.28 
1 (reference)
1.11 
8.00 
1 (reference)
0.56 
NA
1 (reference)
7.20 
NA
0.29 
1.03 
1.04 
1 (reference)
0.63 
0.41 
1 (reference)
1.07 
1.78 
0.98 
0.96 
1.36 
0.29–3.81
0.17–1.92
-
0.13–5.08
NA
0.02–2.62
-
0.41–6.46
0.05–1.69
-
0.24–5.07
0.58–110.27
-
0.15–2.03
NA
-
1.24–41.94
NA
0.08–1.08
0.09–12.32
0.17–6.35
-
0.17–2.32
0.07–2.58
-
0.29–3.92
0.10–31.98
0.93–1.03
0.90–1.01
0.89–2.06
0.946 
0.365 
-
0.832 
NA
0.230 
-
0.487 
0.166 
-
0.892 
0.120 
-
0.376 
NA
-
0.028 
NA
0.064 
0.979 
0.970 
-
0.483 
0.341 
-
0.923 
0.696 
0.327 
0.111 
0.151 
1.41 
1.51 
1 (reference)
1.64 
1.64 
NA
1 (reference)
0.44 
2.14 
1 (reference)
12.67 
NA
1 (reference)
4.09 
NA
1 (reference)
0.48 
1.91 
2.98 
3.11 
0.69 
1 (reference)
1.41 
1.47 
1 (reference)
1.78 
NA
1.03 
1.02 
0.90 
0.41–4.83
0.47–4.89
-
0.29–9.29
0.29–9.29
NA
-
0.10–1.93
0.52–8.81
-
1.46–110.30
NA
-
1.14–14.66
NA
-
0.08–2.71
0.37–9.87
0.70–12.67
0.26–36.87
0.12–4.21
-
0.39–5.13
0.28–7.63
-
0.50–6.37
NA
0.99–1.08
0.98–1.07
0.79–1.03
0.581 
0.492 
-
0.574 
0.574 
NA
-
0.276 
0.291 
-
0.021 
NA
-
0.031 
NA
-
0.403 
0.443 
0.139 
0.368 
0.692 
-
0.602 
0.649 
-
0.377 
NA
0.129 
0.243 
0.129 
OR, odds ratio; CI, confidence interval; NA, not applicable; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Cy, cyclo-
phosphamide; GVHD, graft-versus-host disease; MTX, methotrexate; CR, complete response; FEV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; DLCO, diffusion capacity of carbon monoxide.
*p-values in bold-type represent those that reached statistical significance.
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factors in HSCT was emphasized in a previous investigation 
in which patients were categorized into subgroups based 
on combinations of risk factors, including intensity of the 
conditioning regimen, transplanted cell type, donor type, and 
whether TBI was applied. In that study, treatment outcomes 
and toxicities varied in the different subgroups [29].
In contrast to IP (which significantly affected mortality), 
we found that IPS has less of an effect on TRM and OS (Fig. 
2). This finding was consistent with that of a recent study 
that showed that IP, but not IPS, had a detrimental effect on 
TRM and OS rates [10]. However, the importance of IPS should 
not be discounted, as it contributed considerably to TRM; 
moreover, noninfectious lung toxicity is still reported as a 
contributing cause of death in patients.
In the current study, patients were classified as having 
pulmonary toxicities when they had both clinical symptoms 
and objective evidences on radiographic or pulmonary 
function tests. Although patients could have presented with 
asymptomatic pneumonia, our routine image follow-up 
consisted of plain radiography only, which makes detection 
of asymptomatic pneumonia difficult. Chest computed 
tomography scans were additionally performed when 
pulmonary symptoms were observed. Of 22 patients who were 
classified as not developing IPS or IP, no patient had radiologic 
evidence of pneumonia on plain radiography. This may be 
because mild pulmonary toxicities cannot be easily detected 
through plain radiography.
Our study has several limitations that are inherent to its 
retrospective nature. The sample size was too small to conduct 
a complete statistical analysis. There was a possibility of false-
negative results with respect to pathogen detection, although 
we examined patient specimens using well-established 
techniques to identify the cause of IP. It is also possible that 
the infectious and non-infectious etiologies could overlap, 
so IP might be obscured by pathogen discovery because 
we stratified patients based on the presence or absence of 
concurrent infection dichotomically. However, because similar 
approaches have been used in previous studies, they appear 
reasonable for distinguishing IPS from IP, given the definition 
of IPS [7,10]. 
In conclusion, our data support our hypothesis that IP and 
IPS have distinct risk factors as well as different inherent 
pathogeneses. Our findings demonstrate that multiple 
conditioning regimens may potentially cause patients to be 
at a high risk of developing IP. Patients who received stem 
cells from an unrelated donor had a higher risk of developing 
IPS than those who received stem cells from a matched 
sibling donor. Identifying patients with risk factors for IP and 
IPS before complications develop can lead to appropriate 
preventive strategies and work-ups for early recognition of 
these diseases, which may further reduce mortality due to 
pulmonary complications. 
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Table 4. Multivariate analysis of factors associated with infectious pneumonia and idiopathic pneumonia syndrome
Variable
Infectious pneumonia Idiopathic pneumonia syndrome
OR 95% CI p-value* OR 95% CI p-value*
Donor type
 Matched sibling
 Matched unrelated
 Mismatched related
Cell type
 Bone marrow
 Peripheral blood
 Cord blood
Conditioning regimen
 Cy
 Cy + other
 Other
1 (reference)
0.5
NA
1 (reference)
6.19
NA
-
0.12–2.14
NA
-
0.90–42.56
NA
-
0.352
NA
-
0.064
NA
1 (reference)
12.67
NA
-
1.46–110.30
NA
-
0.021
NA
OR, odds ratio; CI, confidence interval; NA, not applicable; Cy, cyclophosphamide; GVHD, graft-versus-host disease; MTX, methotrexate.
*p-values in bold-type represent those that reached statistical significance. 
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